Literature DB >> 10625648

Appropriate tissue- and cell-specific expression of a single copy human angiotensinogen transgene specifically targeted upstream of the HPRT locus by homologous recombination.

B Cvetkovic1, B Yang, R A Williamson, C D Sigmund.   

Abstract

Development of experimental models by genetic manipulation in mice has proven to be very useful in determining the significance of particular genes in the development of or susceptibility to hypertension. Advances in molecular genetics, transgenic mouse technology, and physiological measurements in mice provided an opportunity to go a step further and develop models to analyze the physiological significance of specific gene variants potentially causing hypertension. In this report, we describe the development of a human angiotensinogen transgenic mouse model generated by targeting the human angiotensinogen gene upstream of the mouse HPRT locus by homologous recombination. The main benefit of this transgenic mouse model is that the human angiotensinogen gene is inserted into the mouse genome as a single copy at a predefined locus and in a specific orientation-a process that can be repeated utilizing other variants of this gene. We establish the validity of this approach by showing that the hAGT(hprt) mice have normal tissue- and cell-specific expression of the human angiotensinogen gene and normally produce and process the hAGT protein at physiological levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10625648     DOI: 10.1074/jbc.275.2.1073

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  A step in another direction: looking for maternal genetic and environmental effects on racial differences in birth weight.

Authors:  E J Van Den Oord; D C Rowe
Journal:  Demography       Date:  2001-11

Review 2.  Gene targeting in the mouse: advances in introduction of transgenes into the genome by homologous recombination.

Authors:  Ravi P Misra; Stephen A Duncan
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

3.  Cardiac expression of Gal4 causes cardiomyopathy in a dose-dependent manner.

Authors:  Petra E M H Habets; Danielle E W Clout; Ronald H Lekanne Deprez; Marian A van Roon; Antoon F M Moorman; Vincent M Christoffels
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

Review 4.  Artificial chromosome-based transgenes in the study of genome function.

Authors:  Jason D Heaney; Sarah K Bronson
Journal:  Mamm Genome       Date:  2006-08-04       Impact factor: 2.957

Review 5.  Transgenic modelling of cytokine polarization in the lung.

Authors:  Charles S Dela Cruz; Min-Jong Kang; Won-Kyung Cho; Chun Geun Lee
Journal:  Immunology       Date:  2010-11-23       Impact factor: 7.397

6.  A growing chain of evidence linking genetic variation in angiotensinogen with essential hypertension: focus on "a haplotype of human angiotensinogen gene containing -217A increases blood pressure in transgenic mice compared with -217G," by Jain et al.

Authors:  Curt D Sigmund
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-10-29       Impact factor: 3.619

7.  Targeted insertion of two Mthfr promoters in mice reveals temporal- and tissue-specific regulation.

Authors:  Laura Pickell; Qing Wu; Xiao-Ling Wang; Daniel Leclerc; Hana Friedman; Alan C Peterson; Rima Rozen
Journal:  Mamm Genome       Date:  2011-07-19       Impact factor: 2.957

8.  Ubiquitous expression of mRFP-1 in vivo by site-directed transgenesis.

Authors:  Ekaterina Yurchenko; Hanna Friedman; Valerie Hay; Alan Peterson; Ciriaco A Piccirillo
Journal:  Transgenic Res       Date:  2006-11-01       Impact factor: 2.788

9.  Site controlled transgenic mice validating increased expression from human matrix metalloproteinase (MMP-1) promoter due to a naturally occurring SNP.

Authors:  Charles I Coon; Steven Fiering; Justin Gaudet; Colby A Wyatt; Constance E Brinckerhoff
Journal:  Matrix Biol       Date:  2009-07-03       Impact factor: 11.583

10.  Dominant lethal pathologies in male mice engineered to contain an X-linked DUX4 transgene.

Authors:  Abhijit Dandapat; Darko Bosnakovski; Lynn M Hartweck; Robert W Arpke; Kristen A Baltgalvis; Derek Vang; June Baik; Radbod Darabi; Rita C R Perlingeiro; F Kent Hamra; Kalpna Gupta; Dawn A Lowe; Michael Kyba
Journal:  Cell Rep       Date:  2014-08-28       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.